Drug discovery and development targeting the life cycle of SARS-CoV-2
A newly emerged coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), belongs to the β-coronavirus family and shows high similarities with SARS-CoV. On March 11, 2020, the World Health Organization (WHO) declared SARS-CoV-2 a global pandemic, and the disease was named the corona...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co. Ltd.
2021-03-01
|
| Series: | Fundamental Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266732582100025X |
| _version_ | 1797976290253340672 |
|---|---|
| author | Haixia Su Yechun Xu Hualiang Jiang |
| author_facet | Haixia Su Yechun Xu Hualiang Jiang |
| author_sort | Haixia Su |
| collection | DOAJ |
| description | A newly emerged coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), belongs to the β-coronavirus family and shows high similarities with SARS-CoV. On March 11, 2020, the World Health Organization (WHO) declared SARS-CoV-2 a global pandemic, and the disease was named the coronavirus disease 2019 (COVID-19). The ongoing COVID-19 pandemic has caused over 46 million infections and over one million deaths worldwide, and the numbers are still increasing. Efficacious antiviral agents are urgently needed to combat this virus. The life cycle of SARS-CoV-2 mainly includes the viral attachment, membrane fusion, genomic replication, assembly and budding of virions. Accordingly, drug development against SARS-CoV-2 currently focuses on blocking spike protein binding to ACE2, inhibiting viral membrane fusion with host cells, and preventing the viral replication by targeting 3C-like protease, papain-like protease, RNA-dependent RNA polymerase as well as some host-cell proteins. In this review, the advances of drug development in these three major areas are elaborated. |
| first_indexed | 2024-04-11T04:48:39Z |
| format | Article |
| id | doaj.art-3bc56640f2ba4d30a19e750df2fa9593 |
| institution | Directory Open Access Journal |
| issn | 2667-3258 |
| language | English |
| last_indexed | 2024-04-11T04:48:39Z |
| publishDate | 2021-03-01 |
| publisher | KeAi Communications Co. Ltd. |
| record_format | Article |
| series | Fundamental Research |
| spelling | doaj.art-3bc56640f2ba4d30a19e750df2fa95932022-12-27T04:41:47ZengKeAi Communications Co. Ltd.Fundamental Research2667-32582021-03-0112151165Drug discovery and development targeting the life cycle of SARS-CoV-2Haixia Su0Yechun Xu1Hualiang Jiang2CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, ChinaCAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China; Corresponding author.CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China; School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, ChinaA newly emerged coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), belongs to the β-coronavirus family and shows high similarities with SARS-CoV. On March 11, 2020, the World Health Organization (WHO) declared SARS-CoV-2 a global pandemic, and the disease was named the coronavirus disease 2019 (COVID-19). The ongoing COVID-19 pandemic has caused over 46 million infections and over one million deaths worldwide, and the numbers are still increasing. Efficacious antiviral agents are urgently needed to combat this virus. The life cycle of SARS-CoV-2 mainly includes the viral attachment, membrane fusion, genomic replication, assembly and budding of virions. Accordingly, drug development against SARS-CoV-2 currently focuses on blocking spike protein binding to ACE2, inhibiting viral membrane fusion with host cells, and preventing the viral replication by targeting 3C-like protease, papain-like protease, RNA-dependent RNA polymerase as well as some host-cell proteins. In this review, the advances of drug development in these three major areas are elaborated.http://www.sciencedirect.com/science/article/pii/S266732582100025XSARS-CoV-2COVID-19Drug developmentAntibodyInhibitors |
| spellingShingle | Haixia Su Yechun Xu Hualiang Jiang Drug discovery and development targeting the life cycle of SARS-CoV-2 Fundamental Research SARS-CoV-2 COVID-19 Drug development Antibody Inhibitors |
| title | Drug discovery and development targeting the life cycle of SARS-CoV-2 |
| title_full | Drug discovery and development targeting the life cycle of SARS-CoV-2 |
| title_fullStr | Drug discovery and development targeting the life cycle of SARS-CoV-2 |
| title_full_unstemmed | Drug discovery and development targeting the life cycle of SARS-CoV-2 |
| title_short | Drug discovery and development targeting the life cycle of SARS-CoV-2 |
| title_sort | drug discovery and development targeting the life cycle of sars cov 2 |
| topic | SARS-CoV-2 COVID-19 Drug development Antibody Inhibitors |
| url | http://www.sciencedirect.com/science/article/pii/S266732582100025X |
| work_keys_str_mv | AT haixiasu drugdiscoveryanddevelopmenttargetingthelifecycleofsarscov2 AT yechunxu drugdiscoveryanddevelopmenttargetingthelifecycleofsarscov2 AT hualiangjiang drugdiscoveryanddevelopmenttargetingthelifecycleofsarscov2 |